February 11, 2009 5:07 PM

Under The Influence

By
Michelle Singer
Jones and Burton agree that the perception of Tauzin's move is not good.

"I mean, when you're pushing so hard for a bill that's controversial and you have to keep the machine open for three hours to get the one vote necessary to pass it, and then, within a matter of months you go to work for the industry that's gonna benefit from it, it does cause you some concern," says Burton.

They are not the only ones cynical about the decision.

"You push this bill through that produces a windfall for the drug companies. And then a short time later, you go to work for the drug lobby at a salary of $2 million. That doesn't look good," Kroft tells Tauzin.

"There was nothing I could've done in my life after leaving Congress that wouldn't have had — I didn't have some impact on in 25 years in Congress … If that looks bad to you, have at it," Tauzin says. "That's the truth."

In fairness to Tauzin and former Medicare chief Tom Scully, they weren't the only public officials involved with the prescription drug bill who later went to work for the pharmaceutical industry.

Just before the vote, Tauzin cited the people who had been most helpful in getting it passed. Among them:

  • John McManus, the staff director of the Ways and Means subcommittee on Health. Within a few months, he left Congress and started his own lobbying firm. Among his new clients was PhRMA, Pfizer, Eli Lilly and Merck.

  • Linda Fishman, from the majority side of the Finance Committee, left to become a lobbyist with the drug manufacturer Amgen.

  • Pat Morrisey, chief of staff of the Energy and Commerce Committee, took a job lobbying for drug companies Novartis and Hoffman-La Roche.

  • Jeremy Allen went to Johnson and Johnson.

  • Kathleen Weldon went to lobby for Biogen, a Bio-tech company.

  • Jim Barnette left to lobby for Hoffman-La Roche.

    In all, at least 15 congressional staffers, congressmen and federal officials left to go to work for the pharmaceutical industry, whose profits were increased by several billion dollars.

    "I mean, they — they have unlimited resources. Unlimited," Burton says. "And when they push real hard to get something accomplished in the Congress of the United States, they can get it done."



    In January, one of the first things the new Democratic House of Representatives did was to make it mandatory for Medicare to negotiate lower prices with the drug companies.

    But a similar measure was blocked in the Senate, due in part to the efforts of the drug lobby.

  • Copyright 2009 CBS. All rights reserved.
    139 Comments +
    Now on your iPhone®, iPad® & iPod touch® Get it now »
    "60 Minutes Sports" on SHOWTIME. Order Now! Order Now »
    60 Minutes on Facebook